Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Subscribe To Our Newsletter & Stay Updated
